Crown Bioscience Launches ‘3D Ex Vivo Patient Tissue Platform’ to Improve Predictability of Immuno-Oncology Drug Candidates
Corporate
October 8, 2021 - Crown Bioscience, a JSR Life Sciences Company, announced the launch of its ‘3D Ex Vivo Patient Tissue Platform’ to improve predictability of immuno-oncology drug candidates.
For more information on Crown Bioscience’s 3D Ex Vivo Patient Tissue Platform, visit Crown Bioscience's webpage on the new service.
Link to PR https://blog.crownbio.com/press/crown-bioscience-launches-3d-ex-vivo-patient-tissue-platform